Piribo: Boehringer Ingelheim, new publication announcement

Boehringer Ingelheim is involved in the manufacturing and marketing of human pharmaceuticals (prescription medicines, consumer health care products), products for industrial customers (chemicals and biopharmaceuticals) and animal health. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.

Boehringer Ingelheim GmbH is the world's largest private pharmaceutical enterprise, encompasses more than 152 affiliates in 45 countries, and employing over 34,000 people. The company's activities are concentrated on two businesses: Human Pharmaceuticals and Animal Health.

Within the Prescription Medicines division, BI markets products in the following therapeutic areas: Respiratory, Cardiovascular, Immunology and Inflammation, Urology, Central Nervous System and Virology. Research and development is focused on developing treatments in the following fields: Respiratory, Cardiovascular, Immunology and Inflammation, Central Nervous System, Virology, Metabolic and Oncology.

Current Growth Drivers
Three of BI's current major products are forecast by Espicom to have sales in excess of EUR 1 billion by 2010, forming the foundations of short to medium growth in the prescription pharmaceutical sector.
Spiriva (tiotropium bromide) is a novel, once-daily, inhaled treatment for chronic obstructive pulmonary disease.
Micardis (telmisartan) is an angiotensin-II receptor blocker for the once-daily treatment of hypertension.
Mobic (meloxicam) is a non-steroidal anti-inflammatory drug for the treatment of rheumatoid arthritis and osteoarthritis.

Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Contents
Executive Summary
Product Portfolio / Research & Development
Appendix 1 - Financial Performance
Appendix 2 - Key Agreements
Appendix 3 - Infrastructure
Appendix 4 - Key Pharmaceutical
Subsidiaries / Joint Ventures

“Boehringer Ingelheim - Prospects to 2010” is available from Piribo. For more information go to: http://www.piribo.com/publications/pharmaceutical_companies/boehringer_ingelheim/boehringer_ingelheim.html

Piribo Product ID: ESP959

About Piribo.
Piribo (http://www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,800 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.